Sage Therapeutics and Biogen reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of patients with essential tremor (ET). The…
With no known treatment and symptoms involving functional decline and the potential for death, Aberdeen University in Scotland recently signed on to a clinical trial…
Wave Life Sciences announced data from the Phase 1b/2a PRECISION-HD2 and PRECISION-HD1 trials evaluating WVE-120102 and WVE-120101, respectively, in Huntington’s disease (HD). Neither trial met…
Brainstorm Cell Therapeutics reported positive topline data from a phase 2 trial assessing three repeated administrations of NurOwn (MSC-NTF cells), each given 2 months apart,…
PaxMedica announced positive results from a phase 2 dose-ranging clinical trial evaluating PAX-124890-=101 demonstrated sustained improvements over placebo in the trial’s primary and several secondary…
AC Immune SA announced positive interim results from its ongoing Phase 1b/2a clinical trial evaluating its first-in-class anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment…
Mesoblast announced results from a Phase 3 trial of its allogeneic mesenchymal precursor cell (MPC) therapy rexlemestrocel-L in patients with chronic low back pain (CLBP)…
Concert Pharmaceuticals reported that its Phase 2 trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did not meet the primary endpoint…
Biogen announced in its annual results and earnings presentation that its Phase II SPARK study of cinpanemab (BIIB054), under development for Parkinson’s disease, missed its primary and…
BioHaven Pharmaceuticals announced the outcome from a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical trial of troriluzole as…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
